Could Ca 2+ sensitizers rescue patients from chronic congestive heart failure?

British Journal of Pharmacology

Volumn 150, Issue 7, 2007, Pages 826-828

  Endoh, M ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Ca 2+ sensitizers; Congestive heart failure; Hypertensive Dahl Rapp rats; Levosimendan; PDE III inhibitors; Remodelling

Indexed keywords

AMRINONE; CALCIUM SENSITIZER; CARDIOTONIC AGENT; CATECHOLAMINE DERIVATIVE; CONTRACTILE PROTEIN; DIGITALIS; LEVOSIMENDAN; MILRINONE; PHOSPHODIESTERASE INHIBITOR; CALCIUM; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; UNCLASSIFIED DRUG;

ACIDOSIS; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; DAHL SALT SENSITIVE RAT; DRUG MECHANISM; ENERGY EXPENDITURE; HEART ARRHYTHMIA; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEMODYNAMICS; HUMAN; LONG TERM CARE; NONHUMAN; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ANIMAL; NOTE; PHYSIOLOGY;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES;

EID: 34047223200     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707163     Document Type: Review

References (11)

1. ++ as an inotropic mechanism. Circulation 73: III-85-III-98.
2. Endoh M (2002). Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 40: 323-338.
3. Endoh M (2003). The therapeutic potential of novel cardiotonic agents. Expert Opin Investig Drugs 12: 735-750.
4. Endoh M, Hori M (2006). Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother 7: 2179-2202.
5. Endoh M, Yanagisawa T, Taira N, Blinks JR (1986). Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 73: III-117-III-133.
6. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H (1998). Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98: 2141-2147.
7. Kopustinskiene DM, Pollesello P, Saris NE (2001). Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 428: 311-314.
8. Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kyto V et al. (2007). Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 150: 851-861 (this issue).
9. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S et al. (2004). Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93: 1309-1312.
10. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30: 1115-1128.
11. 2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br J Pharmacol 145: 1143-1152.